drugset / Trial / NCT04868162
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.
Timeline
- Start
- 2021-04-23
- Primary completion
- 2026-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Becotatug Vedotin | Monoclonal antibody | 2.3 mg/kg | Intravenous |
| Subject | Pucotenlimab | Monoclonal antibody | 3 mg/kg | Intravenous |